Interventions for Tuberculosis Control and Elimination 2002

296. Brodie MJ, Boobis AR, Hillyard CI, Abeyasekera G, Stevenson JC, MacIntyre
I, Park K. Effect of rifampicin and isoniazid on vitamin D metabolism. Clin
Pharmacol Ther 1982; 32: 525-30.
297. Shafer JL, Houston JB. The effect of rifampicin on sulfapyridine plasma concentrations
following sulphalazine administration.
526-8.
Br J Clin Pharmac 1992; 19:
298. Kushner S, Dalalian H, Sanjuro JL, Bach FL, Jr, Safir SR, Smith VK, Jr,
Williams JH. Experimental chemotherapy of tuberculosis. II. The synthesis of
pyrazinamides and related compounds. J Am Chem Soc 1952; 74: 3617-21.
299. Solotorovsky M, Gregory FJ, Isonson EJ, Bugie EJ, O’Neill RC, Pfister K 3rd.
Pyrazinoic acid amide - an agent active against experimental murine tuberculosis.
(19447). Proc Soc Experiment Biol Med 1952; 79: 563-55.
300. Dalmer O, Walter E. Firma E. Merck in Darmstadt. Verfahren zur Herstellung
von Abkömmlingen der Pyrazinmonocarbonsäure. Germany patent 632 257 Klasse
12 p Gruppe 6 M 127990 IV a/12 p. 1934.
301. Zierski M. Pharmakologie, Toxikologie und klinische Anwendung von
Pyrazinamid. Praxis Klin Pneumol 1981; 35: 1075-105.
302. McDermott W, Tompsett R, Stern K. Activation of pyrazinamide and nicotinamide
in acidic environments in vitro. Am Rev Tuberc 1954; 70: 748-54.
303. Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient efflux
of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
J Bacteriol 1999; 181: 2044-9.
304. Rastogi N, Potar MC, David HL. Pyrazinamide is not effective against intracellularly
growing Mycobacterium tuberculosis.
1988; 32: 287.
Antimicrob Agents Chemother
305. Salfinger M, Crowle AJ, Barth Reller L. Pyrazinamide and pyrazinoic acid activity
against tubercle bacilli in cultured human macrophages and in the BACTEC
system. J Infect Dis 1990; 162: 201-7.
306. Raynaud C, Lanéelle MA, Senaratne RH, Draper P, Lanéelle G, Daffé M.
Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of
uptake in addition to lack of pyrazinamidase activity.
1359-67.
Microbiology 1999; 145:
307. Cole ST, Telenti A. Drug resistance in Mycobacterium tuberculosis. Eur Respir
J 1995; 8(suppl 20): 701s-13s.
308. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase /
nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle
bacillus. Nature Med 1996; 2: 662-7.
309. Mestdagh M, Fonteyne PA, Realini L, Rossau R, Jannes G, Mijs W, De Smet
KAL, Portaels F, Van den Eeckhout E. Relationship between pyrazinamide, loss
of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant
clinical isolates of Mycobacterium tuberculosis.
Chemother 1999; 43: 2317-9.
Antimicrob Agents
189